We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Equifax (EFX) Rides on Product Strength, Debt Woes Stay
Read MoreHide Full Article
Equifax Inc. (EFX - Free Report) is currently benefiting from a solid product portfolio and client base diversification.
The company recently reported first-quarter 2021 adjusted earnings of $1.97 per share that beat the Zacks Consensus Estimate by 29.6% and improved on a year-over-year basis. Revenues of $1.21 billion outpaced the consensus estimate by 7.9% and improved 26.6% year over year.
Product Strength, Diversification are Positives
Equifax serves a wide range of industries, such as financial, mortgage, consumer, employees, telecommunications, automotive, commercial, retail, government, resellers, and others. This diversified client base is extremely beneficial, as it helps the company to handle competition from the likes of Verisk Analytics (VRSK - Free Report) , Exponent (EXPO - Free Report) and CBIZ (CBZ - Free Report) , and balance weakness in any sector with strength in the others.
The company is benefiting from a solid product portfolio and clear understanding of the sectors it serves. Customers find considerable significance in the company’s offerings as they use the credit information, and related analytical services and data to process applications for new credit cards, automobile loans, home and equity loans, and other consumer loans.
We believe synergies from acquisitions, in addition to continued general consumer credit activity, product innovation, initiatives to foster enterprise growth and efficient business executions, will boost Equifax’s revenues over the long run.
Debt Woes Stay
Equifax has a debt-laden balance sheet. Total debt at the end of first-quarter 2021 was $4.38 billion, flat sequentially. The company’s cash and cash equivalent of $766 million at the end of the first quarter was well below this debt level, underscoring that the company doesn’t have enough cash to meet this debt burden. Further, the cash level can't meet the short-term debt of $1.1 billion.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%.
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Image: Bigstock
Equifax (EFX) Rides on Product Strength, Debt Woes Stay
Equifax Inc. (EFX - Free Report) is currently benefiting from a solid product portfolio and client base diversification.
The company recently reported first-quarter 2021 adjusted earnings of $1.97 per share that beat the Zacks Consensus Estimate by 29.6% and improved on a year-over-year basis. Revenues of $1.21 billion outpaced the consensus estimate by 7.9% and improved 26.6% year over year.
Product Strength, Diversification are Positives
Equifax serves a wide range of industries, such as financial, mortgage, consumer, employees, telecommunications, automotive, commercial, retail, government, resellers, and others. This diversified client base is extremely beneficial, as it helps the company to handle competition from the likes of Verisk Analytics (VRSK - Free Report) , Exponent (EXPO - Free Report) and CBIZ (CBZ - Free Report) , and balance weakness in any sector with strength in the others.
The company is benefiting from a solid product portfolio and clear understanding of the sectors it serves. Customers find considerable significance in the company’s offerings as they use the credit information, and related analytical services and data to process applications for new credit cards, automobile loans, home and equity loans, and other consumer loans.
We believe synergies from acquisitions, in addition to continued general consumer credit activity, product innovation, initiatives to foster enterprise growth and efficient business executions, will boost Equifax’s revenues over the long run.
Debt Woes Stay
Equifax has a debt-laden balance sheet. Total debt at the end of first-quarter 2021 was $4.38 billion, flat sequentially. The company’s cash and cash equivalent of $766 million at the end of the first quarter was well below this debt level, underscoring that the company doesn’t have enough cash to meet this debt burden. Further, the cash level can't meet the short-term debt of $1.1 billion.
Time to Invest in Legal Marijuana
If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%.
You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>